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Abstract
Corticotropin releasing hormone (CRH) has both neuroendocrine effects, promoting ACTH
release from the anterior pituitary, and neurotransmitter properties, acting on specific neuronal
populations. A recently designed CRH analogue has been shown to be highly potent in preventing
activation of pituitary CRH receptors. The efficacy of this compound, Astressin’, in blocking the
effects of CRH in the central nervous system (CNS) has not been determined. CRH induces
prolonged amygdala-origin seizures in neonatal and infant rats. This model was used in the current
study, to compare Astressin to alpha-helical CRH-(9–41), and to [D-Phe12, Nle21,38, C-
MeLeu37]CRH-(12–41), ie D-Phe-CRH-(12–41). Astressin (3 or 10 μg) was infused into the
cerebral ventricles of infant rats prior to CRH infusion. Both doses of the analogue significantly
delayed the onset of CRH-induced seizures when given 15, but not 30 min before CRH. No effect
of the lower Astressin dose on seizure duration was demonstrated; the higher dose prevented
seizures in 2/12 rats, and delayed seizure onset in the others (22.7 ± 5 min vs 10.1 ± 1.3 min). In
the same paradigm, 10 μg of alpha-helical CRH-(9–41) and 5 μg of D-Phe-CRH-(12–41) had
comparable effects on seizure latency and duration. Electroencephalograms confirmed the
behavioral effects of Astressin. Therefore, in a CNS model of CRH-mediated neurotransmission,
the potency of Astressin is not substantially higher than that of alpha-helical CRH (9–41) and D-
Phe-CRH-(12–41).
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Introduction
Corticotropin releasing hormone (CRH) is a 41-amino acid neuropeptide which activates
target pituitary cells and neurons via specific membrane receptors.1–3 CRH release during
the hormonal response to stress induces the secretion of corticotropin (ACTH) from the
pituitary, an action blocked by analogues which compete for the receptors.4–6 In the central
nervous system, CRH mediates ‘central’ components of the stress response, activating
neurons in amygdala as well as locus ceruleus, hippocampus and cerebellum.7–10 In the
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immature rat, synthetic CRH produces prolonged limbic seizures.11–13 EEG mapping has
been used to localize the origin of these seizures to the amygdala.12
Astressin, an analogue of CRH, {cyclo(30–33)[D-Phe12, Nle21,38, Glu30, Lys33]-rat/human-
CRH-(12–41), was designed and found to be approximately 30 times more potent than [D-
Phe12, Nle21,38]CRH-(12–41) which is equipotent to [D-Phe12, Nle21,38, C-MeLeu37] CRH-
(12–41),6 on ACTH release, in vitro. Astressin was also the most potent CRH analogue for
blocking ACTH release in stressed or adrenalectomized rats in vivo.14 The goal of this study
was to test the efficacy of Astressin in preventing CRH-induced seizures, a model of the
‘central’ effects of CRH.
Materials and methods
Animals
Infant rats (n = 111) were offspring of time-pregnant, Sprague–Dawley rats. They were born
in our federally-approved animal facility, kept on a 12-h light/dark cycle and given access to
unlimited food and water. The time of birth of pups was determined every 12 h, and the day
of birth was considered day 0. Litters were culled to 12 pups and mixed among experimental
groups. Cages were maintained in a quiet, uncrowded room. Pups were implanted with
stainless steel cannulae 24 h prior to experiments,11 and cannula position was verified in all
cases. Peptide infusion was carried out on postnatal days 9–13. Each pup was subjected to
CRH or an antagonist once only.12
Materials
CRH, alpha-helical CRH-(9–41) and [D-Phe12, Nle21,38, C-MeLeu37]CRH-(12–41) (ie D-
Phe-CRH- (12–41)), were purchased from Bachem (Torrance, CA, USA), Astressin,
{cyclo(30–33)[D-Phe12, Nle21,38, Glu30, Lys33]-rat/human CRH-(12–41), was synthesized
as described elsewhere.14 Astressin was dissolved in distilled water. To achieve a 10 μg
μl−1 concentration, the solution was warmed briefly to 60°C.
Experimental design
Experimental groups (n = 5–12) received an antagonist or vehicle 15 or 30 min prior to CRH
infusion. Peptides were administered, using a micro-infusion pump, into the lateral cerebral
ventricle via the indwelling cannula, while the pups were freely moving in a heated
Plexiglas chamber.11–13 CRH dose (0.15 nmol in 1 μl) was chosen to result in significant
(2–3 h long) seizures with a short latency. Subsequent to the infusion of CRH, seizure
latency and duration were monitored for a minimum of 180 min. Animals were scored for
behavioral limbic seizures occurring during 5-min epochs.11,15
The concordance of limbic automatisms and epileptic discharges induced by CRH has been
established previously.12,13 For each dose of Astressin, a separate group of rats was
implanted with bipolar electrodes directed to the amygdala, in addition to cannulae.12
Electroencephalograms (EEGs) were recorded using a Grass 78E polygraph (Grass
Instruments Inc, W Warwick, RI, USA), connected via long, flexible wires to freely moving
animals as described elsewhere.11,12 All infusions were carried out at 8–10 am, to avoid the
potential effects of circadian variability in endogenous CRH levels.16
Statistical analysis was performed using non-parametric tests (Mann–Whitney unpaired two-
tailed comparison, INSTAT software) without assumptions regarding the distribution of
values.
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Results
Administration of 3 μg of Astressin 30 min prior to CRH did not have a significant effect on
seizure latency: time to seizure onset averaged 11.4 ± 3.2 min in rats given Astressin, and
7.5 ± 0.8 min in the control group. Administration of the same dose of Astressin 15 min
prior to CRH resulted in a significant delay of the onset of CRH-induced seizures (Table 1).
Seizure latency in the Astressin group averaged 21.7 ± 3 min (P< 0.05 vs controls). Seizure
duration did not differ significantly among groups. A higher dose of the antagonist, 10 μg,
eliminated CRH seizures entirely in two of twelve rats. In the remainder, latency was
increased, as was observed for the lower dose (22.7 ± 5.0 min).
EEG tracings from amygdala leads of 12-day-old rats subjected to Astressin and CRH are
shown in Figure 1. Panel (a) shows ‘baseline’ bipolar amygdala recording from four rats
(Nos 1–4). The tracing in panel (b) was obtained 3–6 min after the administration of 10 μg
Astressin to rats No. 1 and No. 2. No significant change in background rhythms was
observed. Eight minutes after CRH administration to all four rats (panel c), epileptic
discharges were evident in recordings from rats No. 3 and No. 4. By 45 min after CRH
infusion, seizures were present in EEG tracings of all four rats (panel d).
In a separate group of rats, the administration of Astressin 30 min after CRH infusion did
not abolish the seizures (not shown). Rats receiving Astressin had a higher incidence of wet
dog shakes than those receiving CRH alone.
Table 2 compares the effects of Astressin and those of established CRH antagonists given 15
min prior to CRH, on CRH-induced seizures. As is evident in the table, Astressin was not
significantly superior to alpha-helical CRH-(9–41), or to D-Phe-CRH-(12–41) in either
delaying or attenuating CRH-induced seizures.
Discussion
In this study, the novel inhibitory analogue of CRH, Astressin, was tested for its ability to
prevent seizures induced by CRH administered into the lateral cerebral ventricle of infant
rats. The model of behavioral and electroencephalographic seizures induced by CRH in
neonatal (first postnatal week) and infant rats (second postnatal week) has been established
and characterized.11–13 CRH results in seizures that originate in the amygdala and spread to
other limbic structures.12 The doses required for seizure induction (picomolar range) are
insufficient to activate the pituitary, and do not increase plasma glucocorticoids.11 Elevation
of plasma corticosterone is only evident after the onset of the seizures, which are themselves
stressful.11
CRH-induced seizures are therefore a paradigm of the central effects of the peptide on its
receptor(s). The seizures are blocked by CRH antagonists, but not by, for example,
glutamate receptor antagonists.17 The unique susceptibility of the infant rat to doses of CRH
that do not cause seizures in the adult rodent7 may be a consequence of the developmental
profile of CRH receptors. Receptor-binding and autoradiography studies18,19 have shown
that CRH binding capacity in whole brain and in limbic structures of the rat peaks on the
second postnatal week. We have recently documented that messenger RNA abundance of
the first member of the CRH receptor family, CRF1,20–22 displays a developmental profile
of temporal and spatial distribution which is consistent with these earlier studies:23 receptor-
mRNA levels are maximal in the amygdala on postnatal day 9, and in the hippocampus on
the sixth postnatal day.23 CRF1, is therefore a likely candidate for mediating seizures
induced by CRH in the infant rat.
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CRH-induced seizures provide a paradigm of ‘central’ actions of the peptide, which is
independent of its anxiogenic effect and can be easily quantitated, using both behavioral and
EEG parameters.11,12,15 Astressin has been found, using assays of activation of ‘peripheral’
pituitary receptors,14 to be markedly more potent than D-Phe-CRH-(12–41) and alpha-
helical CRH-(9–41). Using the seizure paradigm, this study failed to demonstrate the
enhanced potency of Astressin as compared with the other two antagonists. A similar result
has been observed in models of the anxiogenic effects of the peptide in adult rats.24 The
reasons for the discrepancy between the ‘central’ and ‘peripheral’ potencies of Astressin are
not clear, but this phenomenon has also been demonstrated for alpha-helical CRH-(9–41).5
The mechanism for the discrepancy between the potency of Astressin in ‘peripheral’ versus
‘central’ assay systems is not obvious. The convulsive effects of CRH are likely mediated by
the first type of CRH receptors, CRF1.20–22 The binding of Astressin to that receptor (Ki =
2.0 nM) is at least ten-fold higher than that of older analogues, excluding decreased receptor
affinity as a cause of the peptide’s relatively low central potency.14 Interaction with a CRH-
binding protein with sequestration of the analogue away from the receptor site should be
considered.25 However, Astressin has very low affinity (Ki > 1000 nM) for the plasma
CRH-binding protein.14 Further, in the current study, the analogue was infused directly into
the cerebrospinal fluid of the lateral ventricles. It is possible that Astressin may fail to reach
target receptors in the amygdala. Diffusion from the lateral ventricles to target neurons may
be hindered by the more rigidly maintained alpha-helical structure of this analogue.14
Alternatively, binding to other neuronal or glial cell-surface molecules cannot be excluded.
In summary, Astressin, a novel inhibitory analogue of CRH, is exceptionally potent in
blocking activation of CRH receptors in the pituitary, but not in eliminating the convulsant
effects of CRH on central nervous system receptors.
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Figure 1.
Electroencephalogram (EEG) obtained from bipolar leads directed at the amygdala of four
12-day-old infant rats (1–4) Panel (a) shows baseline recording. Panel (b) was recorded 3–6
min subsequent to the infusion of 10 μg Astressin to rats No. 1 and No. 2. No significant
change in EEG is evident. Eight minutes after the infusion of CRH (0.15 nmol) to all four
rats, panel (c) demonstrates epileptiform discharges (which were accompanied by
automatisms) in rats No. 3 and No. 4. Rats No. 1 and No. 2 have normal EEGs. Panel (d),
recorded 45 min after CRH administration shows epileptiform discharges in all four rats.
Horizontal bar represents 1 s; vertical bar represents 50 μV.
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Table 1
Effect of Astressin on parameters of CRH-induced seizures
Antagonist n Latency of seizures (min) Seizure duration (min)
None 11 7.5 ± 0.8 237 ± 18
Astressin-30 min 5 11.4 ± 3.2 193 ± 42
Astressin-15 min 12 21.7± 3.0 190 ± 33
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Table 2
Comparison of the effects of three CRH antagonists on latency and duration of CRH-induced seizures
Antagonist n Latency (min) Duration (min)
None 11 7.1 ± 0.8 108.5 ± 13.5
Alpha-helical CRH-(9–41) (10 μg) 12 No seizures (4/12)
21.4 ± 4.4 (8/12)
52.2 ± 14.4
Antagonist effect 14.3 min delay (67%)
No seizures (33%)
56 min reduction (P = 0.014)
None 9 9.11 ± 1.54 137.8 ± 16.6
D-Phe CRH-(12–41) (5 μg) 11 41.3 ± 11.8 (10/11)
No seizures (1/11)
70.8 ± 15.4
Antagonist effect 32.2 min delay (90%)
No seizures (10%)
67 min reduction (P = 0.012)
None 11 7.5 ± 0.9 238.2 ± 20
Astressin (3 μg) 12 21.7 ± 3.1 190.8 ± 34.2
Antagonist effect 13.7 min delay 48 min reduction (P = 0.34)
None 10 10.1 ± 1.3 146.0 ± 14.8
Astressin (10 μg) 12 22.7 ± 5.0 (10/12)
No seizures (2/12)
92.5 ± 20.3
Antagonist effect 12.6 min delay (83.5%)
No seizures (16.5%)
53.5 min reduction (P = 0.037)
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